Table 2.
Baseline Demographics of Patients with CRT at Enrollment in CHAMPION Trial
| Variable | Treatment Group (n=91) | Control Group (n=99) | P Value* |
|---|---|---|---|
| Demographics | |||
| Age, y | 64±13 | 63.7±11.6 | 0.8069 |
| Male, n (%) | 79 (87) | 88 (89) | 0.8243 |
| White, n (%) | 77 (85) | 80 (81) | 0.5670 |
| Laboratory finding | |||
| Body mass index, kg/m2 | 29.2±4.8 | 30.3±7.1 | 0.4661 |
| Systolic blood pressure, mm Hg | 113.9±18.1 | 120.2±20.9 | 0.0391 |
| Heart rate, bpm | 72.1±10.4 | 73.6±10.7 | 0.2319 |
| Creatinine, mg/dL | 1.5±0.5 | 1.4±0.4 | 0.1139 |
| Glomerular filtration rate, mL/min per 1.73 m2 | 55.2±22.2 | 59.1±20.3 | 0.0813 |
| Serum urea nitrogen, mg/dL | 34.2±20.8 | 29.9±17.2 | 0.2565 |
| Ejection fraction, % | 26.0±9.8 | 24.4±9.4 | 0.1019 |
| Hemodynamics | |||
| PA systolic pressure, mm Hg | 43.8±14.4 | 46.9±13.5 | 0.1412 |
| PA diastolic pressure, mm Hg | 18.1±8.4 | 20.8±7.4 | 0.0146 |
| PA mean pressure, mm Hg | 28.4±9.5 | 31.1±8.8 | 0.0626 |
| PA wedge pressure, mm Hg | 18.0±7.7 | 20.4±7.5 | 0.0520 |
| Cardiac output, L/min | 4.2±1.4 | 4.3±1.5 | 0.9671 |
| Cardiac index, L/min per m2 | 2.0±0.6 | 2.0±0.6 | 0.8373 |
| Pulmonary vascular resistance, Wood units | 2.8±1.8 | 2.9±2.0 | 0.5403 |
| Medical history | |||
| Ischemic cardiomyopathy, n (%) | 61 (67) | 73 (74) | 0.3418 |
| Chronic obstructive pulmonary disease, n (%) | 26 (29) | 27 (27) | 0.8724 |
| Coronary artery disease, n (%) | 63 (69) | 78 (79) | 0.1394 |
| Diabetes mellitus, n (%) | 40 (44) | 42 (42) | 0.8839 |
| History of myocardial infarction, n (%) | 50 (55) | 51 (52) | 0.6644 |
| Hyperlipidemia, n (%) | 76 (84) | 77 (78) | 0.3621 |
| Hypertension, n (%) | 62 (68) | 76 (77) | 0.1961 |
| History of atrial fibrillation, n (%) | 51 (56) | 60 (61) | 0.5577 |
| Treatment history | |||
| CRT with implantable cardioverter‐defibrillator, n (%) | 91 (100) | 99 (100) | 1.0000 |
| ACE/ARB, n (%) | 69 (76) | 84 (85) | 0.1430 |
| BB, n (%) | 83 (91) | 90 (91) | 1.0000 |
| ACE/ARB‐ and BB‐guideline‐directed medical therapy, n (%) | 63 (69) | 79 (80) | 0.0985 |
| Aldosterone antagonist, n (%) | 35 (38) | 43 (43) | 0.5554 |
| Loop diuretic, n (%) | 84 (92) | 96 (97) | 0.1988 |
| Thiazide diuretic, n (%) | 12 (13) | 7 (7) | 0.2260 |
| Thiazide diuretic as needed, n (%) | 8 (9) | 10 (10) | 0.8085 |
| Nitrate, n (%) | 22 (24) | 18 (18) | 0.3740 |
| Hydralazine, n (%) | 7 (8) | 9 (9) | 0.7979 |
ACE/ARB indicates angiotensin‐converting enzyme/angiotensin receptor blocker; BB, beta blocker; CHAMPION, CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in New York Heart Association Class III Heart Failure Patients; CRT, cardiac resynchronization therapy; and PA, pulmonary artery.
*
P value testing treatment vs control is from Wilcoxon rank‐sum test or Fisher's exact test.